Equity
MV Lifesciences paid out €265,000 in dividends. That is 171% of the 2025 profit.
MV Lifesciences paid out €265,000 in dividends. That is 171% of the 2025 profit.
The micro format states no turnover.
Short-term debts rose from €79,371 to €349,464.
The 2025 accounts came in latest, 21 days after the end of the period.
Higher net result than 95% of companies in office administrative support. The sector median is €15,202, over 10,299 companies.
In July 2024, 1,603 companies had the same profile as MV Lifesciences has now. Each dot stands for 5 companies, two years later.
Another 0.1% stopped without a precise date, possibly only after those two years.
The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.4% | 0.5% |
| 3 | 0.6% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.4% | 1.6% |
| 7 | 1.7% | 1.8% |
| 8 | 1.9% | 2.0% |
| 9 | 3.1% | 3.3% |
| 10 | 5.9% | 6.4% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,603 companies, not a prediction for MV Lifesciences. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
| Company | ||||
|---|---|---|---|---|
| MV Lifesciences Rixensart | €495,619 | €196,382 | 29.5% | - |
| Marineau Brasschaat | €497,596 | €201,595 | 85.9% | - |
| Biocheck.Gent Dentergem | €478,660 | €216,100 | 61.6% | - |
| LINDEBOS Hasselt | €449,697 | €182,578 | -2.5% | - |
| LATULE Brasschaat | €528,603 | €211,998 | 95.3% | - |
| CVH & Co Consulting Dilbeek | €555,580 | €200,712 | 84.9% | - |
| GIELEN RUBEN Oudsbergen | €571,908 | €197,215 | 55.5% | - |
These companies have the same main activity as MV Lifesciences: other business support services (NACE 82990). They are comparable in size and age: total assets between €450,000 and €572,000, founded between 2021 and 2022.
MV Lifesciences files the micro format. That format states no turnover. The gross margin fell from €199,168 in 2022 to €196,382 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.